| Literature DB >> 26273596 |
Sungjin Park1, Seok Jong Yu2, Yongseong Cho2, Curt Balch3, Jinhyuk Lee4, Yon Hui Kim1, Seungyoon Nam1.
Abstract
Recently, a large clinical study revealed an inverse correlation of individual risk of cancer versus Alzheimer's disease (AD). However, no explanation exists for this anticorrelation at the molecular level; however, inflammation is crucial to the pathogenesis of both diseases, necessitating a need to understand differing signaling usage during inflammatory responses distinct to both diseases. Using a subpathway analysis approach, we identified numerous well-known and previously unknown pathways enriched in datasets from both diseases. Here, we present the quantitative importance of the inflammatory response in the two disease pathologies and summarize signal transduction pathways common to both diseases that are affected by inflammation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26273596 PMCID: PMC4529906 DOI: 10.1155/2015/205247
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1IPA functional enrichment of the CRC and the AD datasets. (a) Top 5 functional categories from “Diseases and Functions” ontology for the datasets are represented. The y-axis represents the minus logarithms of the P values. The higher the value on the y-axis is, the more statistically significant it becomes. The x-axis represents the functional categories. (b) The common genes inversely expressed between the two diseases are indicated by white ovals (see details in Section 2). In the Venn diagrams, “GSE12685 (AD) Dn” is the downregulated gene set in AD patients versus controls. “GSE12685 (AD) Up” is the upregulated gene set in AD patients versus controls. The notation is similar to the GSE1297 (AD) dataset and the GSE4107 (CRC) dataset.
Inflammation-associated genes common to both AD and CRC show opposite expression patterns. The 16 oppositely expressed common genes (in Figure 1(b)) between AD and CRC were assigned to inflammation-associated functional terms in IPA.
| Functional category | Downregulated in AD and upregulated in CRC | Upregulated in AD and downregulated in CRC |
|---|---|---|
| Chemokine | PTPN6+∗#, IRAK3+∗#, FLT3+∗# | BAD+∗#, CD36+∗# |
|
| ||
| Inflammation relating to CRC | DDIT3+∗#, FAS+∗#, IRF3+∗# | |
|
| ||
| Inflammation relating to brain | CCR6+∗#, CD28+∗#, DDIT3+∗#, FAS+∗#, FCER1G+∗#, NGFR+∗# | PPARD+∗# |
|
| ||
| Cytokines relating to cancer | CD28+∗#, FN1+∗# | ABL1+∗#, EGFR+∗# |
|
| ||
| Cytokines relating to brain | CD36+∗# | |
+Genes detected in the CRC network from GSE4107 dataset.
*Genes detected in the AD network from GSE1297 dataset.
#Genes detected in the AD network from GSE12685 dataset.
Subpathways previously not associated with the two diseases. These subpathways were selected from the most significant 100 subpathways in each network. Subpathway (linear signaling flow) with fold-change (the numeral in parenthesis) of the disease group over the control group is represented in each dataset. The most significant 100 subpathways for each dataset are provided in Supplementary Tables S3–S5. The notation in the flow is “B <- A: A activates B” and “B ∣- A: A represses B.”
| KEGG pathway | GSE4107 (CRC) subpathway; | GSE1297 (AD) subpathway; | GSE12685 (AD) subpathway; |
|---|---|---|---|
| Hedgehog signaling (hsa04340) | PTCH1 (1.863) <- GLI2 (2.878) ∣- CSNK1G1 (0.587); 0.000035 | PTCH2 (0.938) <- GLI3 (0.682) ∣- GSK3B (1.513); 0.0015 | |
| WNT3 (3.147) <- GLI2 (2.878) ∣- CSNK1G1 (0.587); 0.000223 | |||
|
| |||
| Axon guidance (hsa04360) | PAK3 (0.732) <- RAC1 (0.943) ∣- PLXNB3 (1.627) <- SEMA4C (1.283); 0.0008 | CFL1 (1.157) ∣- LIMK1 (0.896) <- PAK4 (0.871) <- RAC3 (0.892) <- PLXNA3 (0.954) <- FES (0.841); 0.0011 | |
|
| |||
| WNT signaling (hsa04310) | JUN (4.179) <- TCF7L1 (2.735) <- CTNNB1 (2.562) ∣- GSK3B (0.735) ∣- DVL3 (1.608) <- FZD10 (6.256) <- WNT3 (3.147) <- PORCN (1.279); 0.000114 | ||
| JUN (4.179) <- TCF7L1 (2.735) <- CTNNB1 (2.562) ∣- GSK3B (0.735) ∣- DVL3 (1.608) <- APC2 (2.201) <- AXIN2 (2.307) <- CSNK1A1 (1.963); 0.00016 | |||
|
| |||
| Pathways in cancer (hsa05200) | MMP2 (3.031) <- JUN (4.179) <- MAPK1 (2.425) <- MAP2K1 (1.162) <- ARAF (4.631) <- HRAS (1.027) <- SOS1 (1.624) <- GRB2 (1.613) <- IGF1R (2.299) <- IGF1 (2.529); 0.000022 | ||
|
| |||
| ECM-receptor interaction (hsa04512) | SDC2 (3.091) <- TNC (9.557); 0.000026 | SDC3 (0.849) <- COL5A2 (0.162); 0.003 | SDC1 (0.865) <- COL3A1 (0.865); 0.0017 |
| SDC2 (3.091) <- FN1 (5.594); 0.000125 | |||
|
| |||
| Neurotrophin signaling (hsa04722) | BAD (1.279) ∣- AKT2 (0.856) <- PDK1 (0.943) <- PIK3CD (0.576) <- GAB1 (0.997) <- SHC2 (0.844) <- NTRK1 (0.945) <- NTF3 (0.784); 0.0008 | ||
KEGG pathways associated with the 16 oppositely expressed common genes (in Table 1) in the AD and the CRC networks. From the AD and the CRC networks, pathway information of the 16 genes was obtained. The 16 genes were inversely expressed in the pathways between the AD and the CRC networks.
| Gene symbols | Pathways | CRC (GSE4107) | AD (GSE12685) | AD (GSE1297) |
|---|---|---|---|---|
| PTPN6 | hsa04662_B_cell_receptor_signaling_pathway; hsa04630_Jak-STAT_signaling_pathway; hsa05140_Leishmaniasis | Up | Down | Down |
| IRAK3 | hsa04722_Neurotrophin_signaling_pathway | |||
| FLT3 | hsa05221_Acute_myeloid_leukemia | |||
| DDIT3 | hsa04010_MAPK_signaling_pathway | |||
| FAS | hsa04115_p53_signaling_pathway; hsa04650_Natural_killer_cell_mediated_cytotoxicity | |||
| IRF3 | hsa04622_RIG-I-like_receptor_signaling_pathway; hsa04623_Cytosolic_DNA-sensing_pathway | |||
| CCR6 | hsa04060_Cytokine-cytokine_receptor_interaction; hsa04062_Chemokine_signaling_pathway | |||
| CD28 | hsa04660_T_cell_receptor_signaling_pathway; hsa05416_Viral_myocarditis | |||
| FCER1G | hsa04650_Natural_killer_cell_mediated_cytotoxicity | |||
| NGFR | hsa04722_Neurotrophin_signaling_pathway | |||
| FN1 | hsa04512_ECM-receptor_interaction | |||
|
| ||||
| BAD | hsa04510_Focal_adhesion; hsa05223_Non-small_cell_lung_cancer; hsa05210_Colorectal_cancer | Down | Up | Up |
| CD36 | hsa03320_PPAR_signaling_pathway; hsa04512_ECM-receptor_interaction | |||
| PPARD | hsa05221_Acute_myeloid_leukemia; hsa04310_Wnt_signaling_pathway | |||
| ABL1 | hsa04012_ErbB_signaling_pathway; hsa04722_Neurotrophin_signaling_pathway | |||
| EGFR | hsa05214_Glioma; hsa04012_ErbB_signaling_pathway | |||